Disclaimer: We may earn a commission if you make any purchase by clicking our links. Please see our detailed guide here.

Follow us on:

Google News
Whatsapp

Oxford Scientists Begin Phase I Clinical Trial on Novel HIV Vaccine

IANS
IANS
Meet the voice behind Indo-Asian News Service (IANS), a storyteller navigating the currents of global events with precision and depth. Crafting narratives that bridge cultures, IANS brings you the pulse of the world in every word

Join the Opinion Leaders Network

Join the Techgenyz Opinion Leaders Network today and become part of a vibrant community of change-makers. Together, we can create a brighter future by shaping opinions, driving conversations, and transforming ideas into reality.

Scientists at the University of Oxford have started vaccinations of a novel HIV vaccine candidate as part of a Phase I clinical trial in the UK.

The trial aims to evaluate the safety, tolerability, and immunogenicity of the HIVconsvX vaccine, a mosaic vaccine targeting a broad range of HIV-1 variants, making it potentially applicable for HIV strains in any geographical region.

Thirteen healthy, HIV-negative adults, aged 18-65 and considered not at high risk of infection, will initially receive one dose of the vaccine followed by a further booster dose at four weeks.

An effective HIV vaccine has been elusive for 40 years. This trial is the first in a series of evaluations of this novel vaccine strategy in both HIV-negative individuals for prevention and in people living with HIV for cure,- lead researcher Tomas Hanke, Professor of Vaccine Immunology at the Jenner Institute at Oxford, in a statement.

While most HIV vaccine candidates work by inducing antibodies generated by B-cells, HIVconsvX induces the immune system’s potent, pathogen obliterating T cells, targeting them to highly conserved and therefore vulnerable HIV regions “Achilles heel” common to most HIV variants.

“Achieving protection against HIV is extremely challenging and it is important that we harness the protective potential of both the antibody and T cell arms of the immune system,” said Paola Cicconi, Senior Clinical Research Fellow at the Jenner Institute.

At present, prevention of HIV largely focuses on behavioral and biomedical interventions such as voluntary medical male circumcision, condom use, and anti-retroviral drugs used prior to exposure.

The researchers aim to report the results of the trial by April 2022. Similar trials are also planned in Europe, Africa, and the US.

Recomended

Partner With Us

Digital advertising offers a way for your business to reach out and make much-needed connections with your audience in a meaningful way. Advertising on Techgenyz will help you build brand awareness, increase website traffic, generate qualified leads, and grow your business.

Power Your Business

Solutions you need to super charge your business and drive growth

More from this topic